Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02077166 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Lenalidomide
DRUG: Rituximab

Sponsor

Pharmacyclics LLC.

Collaborators

[object Object]
[object Object]